SCHEMBL1679515

SCHEMBL1679515

CC1CC=CC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266084 1.00
SCHEMBL19202494 1.00
SCHEMBL10296559 0.74
SCHEMBL9830453 0.69
SCHEMBL12826309 0.67
SCHEMBL14084913 0.67
SCHEMBL18322504 0.67
SCHEMBL2754686 0.67
SCHEMBL21535783 0.67
SCHEMBL9832222 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-61118366-A None JP disclosed
EP-4103566-B1 FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS ASTRAZENECA AB (SE) 2023-10-04 EP disclosed
EP-4011877-A2 METHOD OF TREATING ELEVATED PLASMA CHOLESTEROL Institut de Cardiologie de Montréal (CA) 2022-06-15 EP disclosed
WO-2022026892-A1 PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS TANGO THERAPEUTICS, INC. (US) 2022-02-03 WO disclosed
EP-3798214-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2021-03-31 EP disclosed
EP-3186249-B1 PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS SYNGENTA PARTICIPATIONS AG (CH) 2020-12-09 EP disclosed
EP-3294752-B1 PEPTIDE TREATMENT FOR INFLAMMATION AND FIBROSIS UNIV CALIFORNIA (US) 2020-11-04 EP disclosed
US-10660789-B2 1,4-dihydropyridine derivatives with HSP modulating activity RICHTER GEDEON NYRT. (HU) 2020-05-26 US disclosed
US-10653749-B2 Targeting GIV-GEF-GI signaling for treating diverse diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-05-19 US disclosed
CN-110606822-A 1,4-dihydropyridine derivatives having HSP modulating activity 里克特吉迪翁公司 2019-12-24 CN disclosed
US-6383764-B1 ADMINISTERING PEPTIDE OR FUNCTIONAL PEPTIDE ANALOG TO MAMMAL AND DETERMINING ABILITY OF COMPOUND TO CONTROL SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-05-07 US disclosed
US-20020037533-A1 Screening and therapeutic methods for promoting wakefulness and sleep NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-03-28 US disclosed
US-6348567-B1 A PEPTIDE DERIVED FROM STREPTOKINASE; THERAPY FOR NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISEASES, AUTOIMMUNE DISEASES, PARKINSON'S/ALZHEIMER'S/HUNTINGTON'S DISEASES AND INFLAMMATORY DISEASES CV MOLECULAR THERAPEUTICS INC. (CA) 2002-02-19 US disclosed
EP-1171607-A1 STREPTOKINASE FRAGMENTS AND THEIR USE FOR INHIBITING CELL DEATH Rabkin, Simon W. (CA) 2002-01-16 EP disclosed
WO-2000063384-A1 STREPTOKINASE FRAGMENTS AND THEIR USE FOR INHIBITING CELL DEATH RABKIN SIMON W (CA) 2000-10-26 WO disclosed
EP-0157260-B1 4,7-DIHYDROPYRAZOLO(3,4-B)PYRIDINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 1990-06-13 EP disclosed
EP-0362635-A1 Use of nitro-phenyl-dihydropyridine amides as medicaments, compounds and processes for their preparation using intermediates BAYER AG (DE) 1990-04-11 EP disclosed
US-4873334-A HYPOTENSIVE AGENTS, CORONARY VASODILATORS SHIONOGI & CO., LTD. (JP) 1989-10-10 US disclosed
JP-S61118366-A INTERMEDIATE OF 2-METHYLDIHYDROPYRIDINE DERIVATIVE FUJISAWA PHARMACEUT CO LTD 1986-06-05 JP disclosed
EP-0157260-A1 4,7-Dihydropyrazolo(3,4-b)Pyridine derivatives SHIONOGI & CO., LTD. (JP) 1985-10-09 EP disclosed